Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 11

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 11
---
 than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.**

<div align='center'>-6-</div>

BOARD OF DIRECTORS AND CORPORATE GOVERNANCE Composition of the Board Our board of directors currently consists of seven directors, six of whom are independent under the listing standards of The Nasdaq Stock Market LLC, or Nasdaq. Our board of directors is divided into three classes with staggered three-year terms. Thus, at each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the class whose term is then expiring. However, since as a result of the Merger we did not hold an annual meeting of stockholders in 2024, the terms of each of our Class III directors and Class I directors expire at the 2025 annual meeting of stockholders, and thus Class III directors will be elected at our 2025 annual meeting of stockholders to hold office until our 2027 annual meeting of stockholders and Class I directors will be elected at our 2025 annual meeting of stockholders to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified. The following table sets forth the names, ages as of April 14, 2025, and certain other information for each of our directors and director nominees:

| Name                       |     | Class |     | Age |    |     | Position(s)                                                 |     | Director Since |     | Current Term 
      Expires |     | Expiration of 
      Term for 
         Which 
     Nominated |
| Nominees for Director      |     |       |     |     |    |     |                                                             |     |                |     |              |     |               |
| Kimberlee C. Dr